| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 4,227 | 2,057 | 3,375 | 4,129 |
| Cost of revenue | 1,678 | 1,238 | 1,569 | 1,920 |
| Gross profit | 2,549 | 819 | 1,806 | 2,209 |
| Sales and marketing | 1,313 | 1,690 | 1,707 | 1,760 |
| Research and development | 550 | 852 | 988 | 777 |
| General and administrative | 2,088 | 2,252 | 2,551 | 2,311 |
| Total operating expenses | 3,951 | 4,794 | 5,246 | 4,848 |
| Loss from operations | -1,402 | -3,975 | - | -2,639 |
| Interest expense, net | 18 | 65 | 72 | 79 |
| Gain on revaluation of warrant liabilities | 0 | 0 | 1 | 14 |
| Loss on modification of warrant | 0 | 0 | - | - |
| Unrealized gain on foreign exchange | 4 | 1,339 | 626 | 634 |
| Other expense, net | -5 | -8 | -6 | -2 |
| Total other (expense) income, net | -19 | 1,266 | 549 | 567 |
| Net loss | -1,421 | -2,709 | -2,891 | -2,072 |
| Other comprehensive loss | -17 | -1,107 | -533 | -527 |
| Comprehensive loss | -1,438 | -3,816 | -3,424 | -2,599 |
| Diluted average shares | - | - | - | 20,310,000 |
| Net loss per share applicable to common stockholders, basic and diluted (in dollars per share) | -0.54 | -1.24 | -0.12 | -0.1 |
| Us-gaap_earningspersharediluted | -0.54 | -1.24 | -0.12 | -0.1 |
| Weighted average number of common shares outstanding, basic and diluted (in shares) | 2,616,000 | 2,180,000 | 25,393,000 | 20,310,000 |
EKSO BIONICS HOLDINGS, INC. (EKSO)
EKSO BIONICS HOLDINGS, INC. (EKSO)